Shareholders meeting

September 03, 2026 BSE Limited National Stock Exchange of India Ltd., Department of Corporate Relationship Department of Corporate Services 1st Floor, New Trade Ring, Rotunda Building Exchange Plaza, 5th Floor, Phiroze Jeejeebhoy Towers C-1, Block G,Bandra Kurla Complex, Dalal Street, Mumbai- 400001 Bandra (E),Mumbai – 400 051 Scrip Code: 524742 S c r i p C o d e : C A P L I P O I N T . Dear Sir/Madam, Sub: Notice convening the 35th Annual General Meeting (“AGM”) for FY 2025-26 The 35th Annual General Meeting (“AGM”) of the Company is scheduled to be held on Friday, September 25, 2026 at 10.00 A.M (“IST”) through Video Conferencing / Other Audio- Visual Means (“VC/OAVM”), in accordance with the relevant circulars issued by Ministry of Corporate Affairs(“MCA”) and Securities and Exchange Board of India (“SEBI”). We herewith submit the Notice of the 35th AGM for your reference. The Notice is also available on our website at https://www.caplinpoint.net/index.php/annual-report/. AGM Information at glance: Particulars Details Date and Time of AGM Friday, September 25, 2026 at 10.00 A.M. (IST) Mode Video Conferencing (“VC”) / Other Audio Visual Means (“OAVM”) Cut-off date for e-voting Friday, September 18, 2026 E-voting start time and date Tuesday, September 22, 2026 (9.00 A.M. IST) E-voting end time and date Thursday, September 24, 2026 (5.00 P.M. IST) E-voting website of NSDL https://www.evoting.nsdl.com/ This is for your kind information and records. Thanking You, Sincerely yours, For Caplin Point Laboratories Limited Venkatram G General Counsel & Company Secretary Membership No A23989 Encl: A/a coRpoRate oveRview ManageMent RepoRts standalone Financial stateMents consolidated Financial stateMents notice NOTICE NOTICE is hereby given that the 35th Annual General Meeting (“AGM”) of re-enactment(s) thereof for the time being in force, Regulation 17 of the members of Caplin Point Laboratories Limited (“The Company”) will SEBI (Listing Obligations and Disclosure Requirements) Regulations, be held on Friday, September 25, 2026 at 10.00 A.M through Video 2015, and based on the recommendation of the Nomination and Conferencing (“VC”) or other Audio Visual Means (“OAVM”) to transact the Remuneration Committee and approval of Board of Directors, following businesses: Articles of Association of the company, consent of the Members be and is hereby accorded for re-appointment of Dr. Sridhar Ganesan ORDINARY BUSINESS: (DIN: 06819026) as the Managing Director of the Company, who has attained the age of 71 years, for a period of 2 years with effect 1. Adoption of Financial Statements from August 25, 2026 to August 24, 2028, at a remuneration To receive, consider and adopt the Audited Standalone and recommended by the Nomination & Remuneration Committee as set Consolidated Financial Statements of the Company for the Financial out below. year ended March 31, 2026, along with the Reports of the Board of 1. Salary: ` 55,20,000 per annum Directors and the Auditors thereon. 2. Allowances and Perquisites: As may be determined by the 2. Declaration of Final Dividend and ratification of Interim Dividend Nomination and Remuneration Committee including employee To declare a final dividend of ` 4/- (200%) per equity share of ` 2/- stock options. as recommended by the Board of Directors of the Company and to 3. Retirement benefits: Contribution to Provident fund, ratify the Interim Dividend of `4/- (200%) per equity share of ` 2/-, superannuation benefits and gratuity as per the rules of the fund/ aggregating to ` 8/- (400%) for the year ended March 31, 2026. scheme in force from time to time. 3. Retirement by rotation of Dr. Sridhar Ganesan (DIN: 06819026) 4. General: and consideration of his re-appointment i. Perquisites shall be calculated in terms of Income Tax Act, To appoint a Director in place of Dr. Sridhar Ganesan (DIN: 2025 and Rules notified thereunder; 06819026) who retires by rotation, and being eligible, offers himself for re-appointment. ii. The following shall not be considered as part of perquisites: SPECIAL BUSINESS a. Contribution to provident funds, superannuation benefits or annuity funds to the extent that is singly or put together 4. Re-appointment of Dr. Sridhar Ganesan (DIN: 06819026) as the are not taxable under the Income Tax Act, 2025; Managing Director of the Company b. Gratuity payable at a rate not exceeding half a month’s To consider and, if thought fit, to pass the following Resolution as a salary for each completed year of service; and Special Resolution: c. Encashment of leave at the end of the tenure. “RESOLVED THAT pursuant to the provisions of Sections 196, 197, 198, 203 and other applicable provisions, if any, of the Companies iii. The Board/ Nomination and Remuneration Committee shall Act, 2013 (“the Act”), Schedule V thereto and the Rules made have the power to vary the aggregate remuneration (including thereunder including any amendment(s), statutory modification(s) or salary, allowances, perquisites, incentive and retirement Annual Report 2025-26 | 1 benefits) for any Financial Year which shall be subject to an Committee of the Board) or the Company Secretary of the Company, overall ceiling of 5% of the net profit of the Financial Year be and are hereby authorized, to do all acts and take all such steps computed in the manner prescribed under the Act; as may be necessary, proper or expedient to give effect to this resolution.” iv. Dr. Sridhar Ganesan will not be entitled to any sitting fees for attending meetings of the Board and the committees thereof; 6. Appointment of Mr. D Muralidharan (DIN: 08301904) as a Whole Time Director of the Company. v. Dr. Sridhar Ganesan will be subject to all other service conditions as applicable to any other employees of the To consider and, if thought fit, to pass the following Resolution as a Company; Special Resolution vi. Dr. Sridhar Ganesan will be liable to retire by rotation, in “RESOLVED THAT pursuant to the provisions of Sections 152, terms of relevant provisions of Section 152 of the Companies 160, 161, 196, 197, 198, and 203 read with Schedule V and other Act,2013; applicable provisions, if any, of the Companies Act, 2013 (including any statutory modification(s) or re-enactment(s) thereof for the time RESOLVED FURTHER THAT the Board of Directors of the Company being in force), the Companies (Appointment and Remuneration of (which term shall include the Nomination and Remuneration Managerial Personnel) Rules, 2014, and Regulation 17 and other Committee of the Board) or the Company Secretary of the Company, applicable regulations of the SEBI (Listing Obligations and Disclosure be and are hereby authorized, to do all acts and take all such steps Requirements) Regulations, 2015, and the Articles of Association of as may be necessary, proper or expedient to give effect to this the Company, and based on the recommendation of the Nomination resolution.” and Remuneration Committee and the Board of Directors, Mr. D 5. Continuation of Mr. C. C. Paarthipan (DIN: 01218784) as the Muralidharan (DIN: 08301904), who was appointed as an Additional Chairman and Non-Executive, Non-Independent Director of the Director, be and is hereby appointed as a Whole Time Director of the Company. Company, for a term of two (2) consecutive years (“Term”) with effect from August 12, 2026 to August 11, 2028. To consider and, if thought fit, to pass the following Resolution as a Special Resolution. RESOLVED FURTHER THAT taking into account the recommendation of the Nomination and Remuneration Committee and the Board of “RESOLVED THAT pursuant to the provisions of Regulation 17(1A) Directors, approval of members be and is hereby accorded to the and other applicable provisions of the SEBI (Listing Obligations appointment of Mr. D Muralidharan (DIN: 08301904) for the term, and Disclosure Requirements) Regulations, 2015 (“SEBI Listing notwithstanding the fact that he has attained the age of 70 years, on Regulations”), the Artic [Showing first 8,000 characters — download PDF for full document]